Can gabapentin (Neurontin) cause Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) in patients, particularly the elderly or those with a history of neurological conditions?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 27, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Gabapentin Cause SIADH?

Gabapentin is not established as a cause of SIADH based on current guideline evidence, though structurally related pregabalin has rare case reports of SIADH. The major guidelines on SIADH do not list gabapentin among the well-documented medication causes of this syndrome.

Evidence from SIADH Guidelines

The comprehensive guidelines on SIADH causes identify specific high-risk medication classes but notably do not include gabapentin 1, 2:

  • Established medication causes of SIADH include: SSRIs, SNRIs, carbamazepine, oxcarbazepine, NSAIDs, tramadol, certain antipsychotics, platinum-based chemotherapy (cisplatin), vinca alkaloids (vincristine, vinblastine), cyclophosphamide, and opioids 1, 2

  • Antiepileptic drugs specifically associated with SIADH are carbamazepine and oxcarbazepine, which have moderate to high level evidence 1

  • The 2019 American Geriatrics Society Beers Criteria, which comprehensively lists medications associated with SIADH in vulnerable populations, does not include gabapentin 1

Related Drug Evidence: Pregabalin

While gabapentin itself is not listed, pregabalin (a structurally related calcium channel α2-δ subunit ligand) has a single case report of SIADH 3:

  • A 2016 case report documented pregabalin-induced hyponatremia meeting SIADH criteria, with rapid improvement after drug discontinuation 3

  • However, this represents extremely rare occurrence and is not reflected in major SIADH guidelines 3

  • Pregabalin's known adverse effects include CNS disturbance, peripheral edema, and weight gain, but hyponatremia is rarely reported 3

Clinical Context for Gabapentin Use

Gabapentin is used for neuropathic pain in diabetic neuropathy and has shown efficacy, though it is not FDA-approved for this specific indication 4:

  • Common adverse effects in older patients may be more severe and can be attenuated by lower starting doses and gradual titration 4

  • The drug is generally considered to have a favorable safety profile compared to other neuropathic pain medications 4

Critical Clinical Pitfalls

If hyponatremia develops in a patient taking gabapentin, consider these more likely culprits first:

  • Concurrent medications with established SIADH risk: SSRIs, carbamazepine, NSAIDs, or thiazide diuretics, especially in combination 1, 5

  • Polypharmacy risk: The concurrent use of multiple CNS agents increases SIADH risk substantially 1

  • Thiazide-SSRI combination: This pairing substantially increases hyponatremia risk and is particularly dangerous 1

  • Elderly patients: Aging increases sensitivity to hyponatremia due to reduced glomerular filtration rate 1

  • Alternative diagnoses: Malignancy (especially small cell lung cancer), CNS disorders, pulmonary infections, or cerebral salt wasting in neurosurgical patients 2, 6

Monitoring Recommendations

If gabapentin is suspected (despite lack of guideline evidence):

  • Check serum sodium, plasma osmolality, urine osmolality, and urine sodium to confirm SIADH diagnosis (serum sodium <134 mEq/L, plasma osmolality <275 mosm/kg, urine osmolality >500 mosm/kg, urine sodium >20 mEq/L) 1

  • Exclude hypothyroidism and adrenal insufficiency before diagnosing SIADH 1, 2

  • Serum uric acid <4 mg/dL has 73-100% positive predictive value for SIADH 2

  • Discontinue the suspected medication and observe for improvement, as drug-induced SIADH typically resolves after cessation 5, 7

References

Guideline

Management of Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Syndrome of Inappropriate Antidiuretic Hormone Secretion Causes and Diagnosis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Non-Pharmacological Causes of SIADH

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.